2024

Hageman, S. H..J. et al. (2024) Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. European Journal of Preventive Cardiology, (Accepted for Publication)

Björnson, E., Adiels, M., Taskinen, M.-R., Burgess, S., Chapman, M. J., Packard, C. J. and Borén, J. (2024) Lipoprotein(a) is markedly more atherogenic than LDL an apolipoprotein B-based genetic analysis. Journal of the American College of Cardiology, 83(3), pp. 385-395. (doi: 10.1016/j.jacc.2023.10.039) (PMID:38233012)

2023

Chapman, M. J. and Packard, C. J. (2023) Realizing the potential of PCSK9 inhibition: a novel oral macrocyclic peptide on the horizon. Journal of the American College of Cardiology, 81(16), pp. 1565-1568. (doi: 10.1016/j.jacc.2023.03.384) (PMID:37076210)

2022

Taskinen, M.-R. et al. (2022) Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism. European Journal of Endocrinology, 187(1), pp. 75-84. (doi: 10.1530/eje-21-1187) (PMID:35521766)

Packard, C. J. (2022) Remnants, LDL, and the quantification of lipoprotein-associated risk in atherosclerotic cardiovascular disease. Current Atherosclerosis Reports, 24(3), pp. 133-142. (doi: 10.1007/s11883-022-00994-z) (PMID:35175548)

2021

Taskinen, M.‐R. et al. (2021) Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes. Diabetes, Obesity and Metabolism, 23(5), pp. 1191-1201. (doi: 10.1111/dom.14328) (PMID:33502078)

2020

Björnson, E. et al. (2020) Apolipoprotein B48 metabolism in chylomicrons and very low‐density lipoproteins and its role in triglyceride transport in normo‐ and hypertriglyceridemic human subjects. Journal of Internal Medicine, 288(4), pp. 422-438. (doi: 10.1111/joim.13017) (PMID:31846520)

Boren, J. et al. (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 41(24), pp. 2313-2330. (doi: 10.1093/eurheartj/ehz962) (PMID:32052833) (PMCID:PMC7308544)

Björnson, E., Packard, C. J. , Taskinen, M.‐R. and Borén, J. (2020) ‘Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate.’ – Authors’ response. Journal of Internal Medicine, 287(1), p. 118. (doi: 10.1111/joim.12997) (PMID:31631432)

Packard, C. J. (2020) Triglyceride lowering 2.0: back to the future? European Heart Journal, 41(1), pp. 95-98. (doi: 10.1093/eurheartj/ehz810) (PMID:31733059)

Taskinen, M.-R. et al. (2020) Impact of PCSK9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type 2 diabetic subjects. Journal of Clinical Lipidology, 14(1), pp. 77-87. (doi: 10.1016/j.jacl.2019.12.003) (PMID:31917184)

2019

Packard, C. J. (2019) Strategies to alter the trajectory of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 30(6), pp. 438-445. (doi: 10.1097/MOL.0000000000000643) (PMID:31609725)

Ference, B. A. et al. (2019) Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA: Journal of the American Medical Association, 322(14), pp. 1381-1391. (doi: 10.1001/jama.2019.14120) (PMID:31475726) (PMCID:PMC6724415)

Lee, M. M.Y. , Sattar, N. , McMurray, J. J.V. and Packard, C. J. (2019) Statins in the prevention and treatment of heart failure: a review of the evidence. Current Atherosclerosis Reports, 21(10), 41. (doi: 10.1007/s11883-019-0800-z)

Taskinen, M.-R., Packard, C. J. and Borén, J. (2019) Dietary fructose and the Metabolic Syndrome. Nutrients, 11(9), e1987. (doi: 10.3390/nu11091987) (PMID:31443567)

Adiels, M. et al. (2019) Role of apolipoprotein C-III overproduction in diabetic dyslipidemia. Diabetes, Obesity and Metabolism, 21(8), pp. 1861-1870. (doi: 10.1111/dom.13744) (PMID:30972934)

Fruchart, J.-C. et al. (2019) Residual vascular risk in diabetes – will the SPPARM alpha concept hold the key? Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 13(4), pp. 2723-2725. (doi: 10.1016/j.dsx.2019.05.034) (PMID:31405699)

Fruchart, J.-C. et al. (2019) The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular Diabetology, 18(1), 71. (doi: 10.1186/s12933-019-0864-7) (PMID:31164165) (PMCID:PMC6549355)

Brazel, D. M. et al. (2019) Exome chip meta-analysis fine maps causal variants and elucidates the genetic architecture of rare coding variants in smoking and alcohol use. Biological Psychiatry, 85(11), pp. 946-955. (doi: 10.1016/j.biopsych.2018.11.024) (PMID:30679032)

Taskinen, M.-R., Packard, C. J. and Borén, J. (2019) Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Current Atherosclerosis Reports, 21(8), 27. (doi: 10.1007/s11883-019-0791-9) (PMID:31111320) (PMCID:PMC6527792)

Björnson, E. et al. (2019) Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics. Journal of Internal Medicine, 285(5), pp. 562-577. (doi: 10.1111/joim.12877) (PMID:30779243)

Armitage, J. et al. (2019) Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, 393(10170), pp. 407-415. (doi: 10.1016/S0140-6736(18)31942-1) (PMID:30712900) (PMCID:PMC6429627)

Ference, B. A. et al. (2019) Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA: Journal of the American Medical Association, 321(4), pp. 364-373. (doi: 10.1001/jama.2018.20045) (PMID:30694319) (PMCID:PMC6439767)

2018

Robinson, J. G. et al. (2018) Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life. Journal of the American Heart Association, 7(20), e009778. (doi: 10.1161/JAHA.118.009778) (PMID:30371276) (PMCID:PMC6474943)

Packard, C. J. (2018) Determinants of achieved LDL cholesterol and "Non-HDL" cholesterol in the management of dyslipidemias. Current Cardiology Reports, 20(8), 60. (doi: 10.1007/s11886-018-1003-x) (PMID:29904807)

Annemans, L., Packard, C. J. , Briggs, A. and Ray, K. K. (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 39(27), pp. 2546-2550. (doi: 10.1093/eurheartj/ehx710) (PMID:29236976) (PMCID:PMC6047410)

Fisk, H. L. et al. (2018) Association of oily fish intake, sex, age, BMI and APOE genotype with plasma long-chain n-3 fatty acid composition. British Journal of Nutrition, 120(1), pp. 23-32. (doi: 10.1017/S000711451800106X) (PMID:29729672)

Burgess, S. et al. (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies. JAMA Cardiology, 3(7), pp. 619-627. (doi: 10.1001/jamacardio.2018.1470) (PMID:29926099)

Packard, C. J. (2018) LDL cholesterol: how low to go? Trends in Cardiovascular Medicine, 28(5), pp. 348-354. (doi: 10.1016/j.tcm.2017.12.011) (PMID:29336946)

Vallejo-Vaz, A. J., Packard, C. J. and Ray, K. K. (2018) Response by Vallejo-Vaz et al to letters regarding article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up". Circulation, 137(22), pp. 2419-2420. (doi: 10.1161/CIRCULATIONAHA.118.033781) (PMID:29844078)

Turcot, V. et al. (2018) Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 50(1), pp. 26-41. (doi: 10.1038/s41588-017-0011-x) (PMID:29273807) (PMCID:PMC5945951)

2017

Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J. , Ford, I. and Ray, K. K. (2017) Low-density lipoprotein-cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein-cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation, 136(20), pp. 1878-1891. (doi: 10.1161/CIRCULATIONAHA.117.027966) (PMID:28877913)

Packard, C. J. , Young, R. , Ross, K., Ford, I. , Ambegaonkar, B. M., Brudi, P. and McCowan, C. (2017) Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. European Heart Journal: Quality of Care and Clinical Outcomes, 3(4), pp. 281-288. (doi: 10.1093/ehjqcco/qcx012) (PMID:29044395)

Robertson, J., Porter, D., Sattar, N. , Packard, C. J. , Caslake, M., McInnes, I. and McCarey, D. (2017) Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(11), pp. 1949-1952. (doi: 10.1136/annrheumdis-2017-211708) (PMID:28916714)

Ference, B. A. et al. (2017) Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA: Journal of the American Medical Association, 318(10), pp. 947-956. (doi: 10.1001/jama.2017.11467) (PMID:28846118) (PMCID:PMC5710502)

Ference, B. A. et al. (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), pp. 2459-2472. (doi: 10.1093/eurheartj/ehx144) (PMID:28444290)

Gregson, J. M. et al. (2017) Genetic invalidation of Lp-PLA2 as a therapeutic target: large-scale study of five functional Lp-PLA2-lowering alleles. European Journal of Preventive Cardiology, 24(5), pp. 492-504. (doi: 10.1177/2047487316682186) (PMID:27940953)

Sodi, R., Eastwood, J., Caslake, M., Packard, C. J. and Denby, L. (2017) Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. Clinica Chimica Acta, 466, pp. 13-19. (doi: 10.1016/j.cca.2016.12.031) (PMID:28062296)

Marouli, E. et al. (2017) Rare and low-frequency coding variants alter human adult height. Nature, 542(7640), pp. 186-190. (doi: 10.1038/nature21039) (PMID:28146470) (PMCID:PMC5302847)

Bassendine, M.F., Nielsen, S.U., Bridge, S.H., Felmlee, D.J., Sheridan, D.A., Packard, C.J. and Neely, R.D. (2017) Hepatitis C virus and atherosclerosis: a legacy after virologic cure? Clinics and Research in Hepatology and Gastroenterology, 41(1), pp. 25-30. (doi: 10.1016/j.clinre.2016.09.008) (PMID:27840032)

Packard, C. J. (2017) Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism. Circulation, 135(4), pp. 363-365. (doi: 10.1161/CIRCULATIONAHA.116.025897) (PMID:28115413)

2016

Ford, I. , Shah, A. S.V., Zhang, R., McAllister, D. A. , Strachan, F. E., Caslake, M., Newby, D. E., Packard, C. J. and Mills, N. L. (2016) High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. Journal of the American College of Cardiology, 68(25), pp. 2719-2728. (doi: 10.1016/j.jacc.2016.10.020) (PMID:28007133) (PMCID:PMC5176330)

Surendran, P. et al. (2016) Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 48(10), pp. 1151-1161. (doi: 10.1038/ng.3654) (PMID:27618447) (PMCID:PMC5056636)

Scott, R. A. et al. (2016) A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 8(341), 341ra76. (doi: 10.1126/scitranslmed.aad3744) (PMID:27252175)

Ford, I. , Murray, H., Mccowan, C. and Packard, C. J. (2016) Long term safety and efficacy of lowering LDL cholesterol with statin therapy: 20-year follow-up of West of Scotland coronary prevention study. Circulation, 133(11), pp. 1073-1080. (doi: 10.1161/CIRCULATIONAHA.115.019014) (PMID:26864092) (PMCID:PMC4894764)

Zanoni, P. et al. (2016) Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 351(6278), pp. 1166-1171. (doi: 10.1126/science.aad3517) (PMID:26965621) (PMCID:PMC4889017)

Minihane, A. M. et al. (2016) Consumption of fish oil providing amounts of eicosapentaenoic acid and docosahexaenoic acid that can be obtained from the diet reduces blood pressure in adults with systolic hypertension: a retrospective analysis. Journal of Nutrition, 146(3), pp. 516-523. (doi: 10.3945/jn.115.220475) (PMID:26817716)

2015

Packard, C. and Ford, I. (2015) Long-term follow-up of lipid-lowering trials. Current Opinion in Lipidology, 26(6), pp. 572-579. (doi: 10.1097/mol.0000000000000230) (PMID:26780010)

Packard, C. J. , Weintraub, W. S. and Laufs, U. (2015) New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. Vascular Pharmacology, 71, pp. 37-39. (doi: 10.1016/j.vph.2015.03.008) (PMID:25889746)

Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi: 10.1093/eurheartj/ehv072) (PMID:25802390) (PMCID:PMC4769322)

Cholesterol Treatment Trialists’ (CTT) Collaboration, and , (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet, 385(9976), pp. 1397-1405. (doi: 10.1016/S0140-6736(14)61368-4)

van Leeuwen, E. M. et al. (2015) Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels. Nature Communications, 6, 6065. (doi: 10.1038/ncomms7065) (PMID:25751400) (PMCID:PMC4366498)

2014

Akao, H. et al. (2014) ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. Atherosclerosis, 235(1), pp. 176-181. (doi: 10.1016/j.atherosclerosis.2014.04.030) (PMID:24854628)

Preiss, D. and Packard, C. J. (2014) Emerging therapeutic approaches to treat dyslipidemia. Current Cardiology Reports, 16(7), (doi: 10.1007/s11886-014-0506-3) (PMID:24890766)

Preiss, D. , Lloyd, S. M. , Ford, I. , McMurray, J. J.V. , Holman, R. R., Welsh, P. , Fisher, M., Packard, C. J. and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi: 10.1016/S2213-8587(13)70152-9) (PMID:24622715)

Laufs, U., Descamps, O. S., Catapano, A. L. and Packard, C. J. (2014) Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. European Heart Journal, 35(30), pp. 1996-2000. (doi: 10.1093/eurheartj/ehu228)

McConnachie, A. , Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C.J. , Cobbe, S.M. and Ford, I. (2014) Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal, 35(5), pp. 290-298. (doi: 10.1093/eurheartj/eht232)

2013

Cavanagh, J. et al. (2013) Socioeconomic status and the cerebellar grey matter volume. Data from a well-characterised population sample. Cerebellum, 12(6), pp. 882-891. (doi: 10.1007/s12311-013-0497-4)

Krishnadas, R. , Kim, J., Mclean, J., Batty, D., Mclean, J., Millar, K., Packard, C. and Cavanagh, J. (2013) The envirome and the connectome: exploring the structural noise in the human brain associated with socioeconomic deprivation. Frontiers in Human Neuroscience, 7(722), (doi: 10.3389/fnhum.2013.00722)

Krishnadas, R. et al. (2013) Socioeconomic deprivation and cortical morphology: psychological, social, and biological determinants of ill health study. Psychosomatic Medicine, 75(7), pp. 616-623. (doi: 10.1097/PSY.0b013e3182a151a7)

Krishnadas, R. et al. (2013) Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: results from the psychological, social and biological determinants of ill health (pSoBid) study. NeuroImage: Clinical, 2(2013), pp. 646-657. (doi: 10.1016/j.nicl.2013.04.012)

Laufs, U., Weintraub, W.S. and Packard, C.J. (2013) Beyond statins: what to expect from add-on lipid regulating therapy? European Heart Journal, 34(34), pp. 2660-2665. (doi: 10.1093/eurheartj/eht213)

Lloyd, S.M. et al. (2013) Long-term effects of statin treatment in elderly people: Extended follow-up of the PROspective study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE, 8(9), e72642. (doi: 10.1371/journal.pone.0072642) (PMID:24023757) (PMCID:PMC3759378)

Millar, K. et al. (2013) Personality, socio-economic status and inflammation: cross-sectional, population-based study. PLoS ONE, 8(3), e58256. (doi: 10.1371/journal.pone.0058256) (PMID:23516457) (PMCID:PMC3596406)

Welsh, P. , Doolin, O., Willeit, P., Packard, C. , Macfarlane, P., Cobbe, S., Gudnason, V., Di Angelantonio, E., Ford, I. and Sattar, N. (2013) N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. European Heart Journal, 34(6), pp. 443-450. (doi: 10.1093/eurheartj/ehs239)

2012

McLean, J. et al. (2012) Early life socioeconomic status, chronic physiological stress and hippocampal N-acetyl aspartate concentrations. Behavioural Brain Research, 235(2), pp. 225-230. (doi: 10.1016/j.bbr.2012.08.013)

Packard, C. et al. (2012) Interaction of personality traits with social deprivation in determining mental wellbeing and health behaviours. Journal of Public Health, 34(4), pp. 615-624. (doi: 10.1093/pubmed/fds030)

Miller, A. M. et al. (2012) Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS ONE, 7(10), e47830. (doi: 10.1371/journal.pone.0047830) (PMID:23112853) (PMCID:PMC3480428)

Kaptoge, S. et al. (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. New England Journal of Medicine, 367(14), pp. 1310-1320. (doi: 10.1056/NEJMoa1107477)

Mihaylova, B. et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 380(9841), pp. 581-590. (doi: 10.1016/S0140-6736(12)60367-5)

Knox, S. et al. (2012) 25-hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis, 223(2), pp. 437-441. (doi: 10.1016/j.atherosclerosis.2012.05.001) (PMID:22632919)

Di Angelantonio, E. et al. (2012) Lipid-related markers and cardiovascular disease prediction. JAMA: Journal of the American Medical Association, 307(23), pp. 2499-2506. (doi: 10.1001/jama.2012.6571)

Martin, N.G., Li, K.W., Murray, H., Putt, W., Packard, C.J. and Humphries, S.E. (2012) The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. British Journal of Clinical Pharmacology, 73(2), pp. 303-306. (doi: 10.1111/j.1365-2125.2011.04090.x)

McGuinness, D. et al. (2012) Socio-economic status is associated with epigenetic differences in the pSoBid cohort. International Journal of Epidemiology, 41(1), pp. 151-160. (doi: 10.1093/ije/dyr215)

Akao, H. et al. (2012) Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis, 220(2), pp. 413-417. (doi: 10.1016/j.atherosclerosis.2011.09.028)

Akao, H. et al. (2012) KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis, 220(2), pp. 456-462. (doi: 10.1016/j.atherosclerosis.2011.11.037)

Charchar, F.J. et al. (2012) Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet, 379(9819), pp. 915-922. (doi: 10.1016/S0140-6736(11)61453-0)

Emberson, J.R. et al. (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE, 7(1), e29849. (doi: 10.1371/journal.pone.0029849) (PMID:22276132) (PMCID:PMC3261846)

Kofler, B.M. et al. (2012) Apolipoprotein E genotype and the cardiovascular disease risk phenotype: Impact of sex and adiposity (the FINGEN study). Atherosclerosis, 221(2), pp. 467-470. (doi: 10.1016/j.atherosclerosis.2012.01.042)

Poortvliet, R.K.E. et al. (2012) Blood pressure variability and cardiovascular risk in the PROspective study of pravastatin in the elderly at risk (PROSPER). PLoS ONE, 7(12), e52438. (doi: 10.1371/journal.pone.0052438) (PMID:23285043) (PMCID:PMC3527505)

Shiffman, D. et al. (2012) Genome-wide study of gene variants associated with differential cardiovascular event reduction by Pravastatin therapy. PLoS ONE, 7(5), e38240. (doi: 10.1371/journal.pone.0038240) (PMID:22666496) (PMCID:PMC3364212)

2011

Ford, I. et al. (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology, 40(6), pp. 1530-1538. (doi: 10.1093/ije/dyr172)

van Es, A.C.G.M. et al. (2011) Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology, 77(15), pp. 1446-1452. (doi: 10.1212/WNL.0b013e318232ab1d)

Welsh, P. et al. (2011) Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(10), pp. 2338-2344. (doi: 10.1161/ATVBAHA.111.231795) (PMID:21757655)

Widya, R. L. et al. (2011) Increased amygdalar and hippocampal volumes in elderly obese individuals with or at risk of cardiovascular disease. American Journal of Clinical Nutrition, 93(6), pp. 1190-1195. (doi: 10.3945/ajcn.110.006304)

Logue, J. , Murray, H.M., Welsh, P. , Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2011) Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart, 97(7), pp. 564-568. (doi: 10.1136/hrt.2010.211201)

Rahimi, K. et al. (2011) Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. British Medical Journal, 342, d1250. (doi: 10.1136/bmj.d1250)

Wensley, F. et al. (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. British Medical Journal, 342, d548-d548. (doi: 10.1136/bmj.d548)

Moran, C.N., Barwell, N.D., Malkova, D. , Cleland, S., McPhee, I., Packard, C.J. , Zammit, V.A. and Gill, J.M.R. (2011) Effects of diabetes family history and exercise training on the expression of adiponectin and leptin and their receptors. Metabolism, 60(2), pp. 206-214. (doi: 10.1016/j.metabol.2009.12.026)

Li, Y. et al. (2011) Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics, 129(1), pp. 17-23. (doi: 10.1007/s00439-010-0892-6)

Mutsaerts, H.J.M.M. et al. (2011) Diastolic carotid artery wall shear stress is associated with cerebral infarcts and periventricular white matter lesions. Stroke, 42(12), pp. 3497-3501. (doi: 10.1161/STROKEAHA.111.614453)

Packard, C.J. et al. (2011) Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study. BMC Public Health, 11, p. 42. (doi: 10.1186/1471-2458-11-42)

Pons, D. et al. (2011) Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. Heart, 97(2), pp. 143-150. (doi: 10.1136/hrt.2010.199927)

Shiels, P.G. et al. (2011) Accelerated telomere attrition is associated with relative household income, diet and inflammation in the pSoBid cohort. PLoS ONE, 6(7), e22521. (doi: 10.1371/journal.pone.0022521)

2010

Felmlee, D. J. et al. (2010) Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology, 139(5), pp. 1774-1783. (doi: 10.1053/j.gastro.2010.07.047) (PMID:20682323)

Caslake, M.J. et al. (2010) Lipoprotein-associated phospholipase A₂ inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis, 210(1), pp. 28-34. (doi: 10.1016/j.atherosclerosis.2009.10.041)

Polisecki, E. et al. (2010) Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 51(5), pp. 1201-1207. (doi: 10.1194/jlr.P001172)

Olano-Martin, E., Anil, E., Caslake, M.J., Packard, C.J. , Bedford, D., Stewart, G., Peiris, D., Williams, C.M. and Minihane, A.M. (2010) Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis, 209(1), pp. 104-110. (doi: 10.1016/j.atherosclerosis.2009.08.024)

Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi: 10.1016/S0140-6736(09)61965-6)

Matthan, N.R., Resteghini, N., Robertson, M., Ford, I. , Shepherd, J., Packard, C. , Buckley, B.M., Jukema, J.W., Lichenstein, A.H. and Schaefer, E.J. (2010) Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. Journal of Lipid Research, 51, pp. 202-209. (doi: 10.1194/jlr.M900032-JLR200)

Trompet, S. et al. (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology, 257(1), pp. 85-90. (doi: 10.1007/s00415-009-5271-7)

Welsh, P. et al. (2010) Unraveling the directional link between adiposity and inflammation: a bidirectional mendelian randomization approach. Journal of Clinical Endocrinology and Metabolism, 95(1), pp. 93-99. (doi: 10.1210/jc.2009-1064)

Dow, D.J., McMahon, A.D. , Gray, I.C., Packard, C.J. and Groot, P.H.E. (2010) CCR2 and coronary artery disease: a woscops substudy. BMC Research Notes, 3(1), p. 31. (doi: 10.1186/1756-0500-3-31)

Preiss, D. , Welsh, P. , Murray, H., Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up(dagger). European Heart Journal, 31(10), pp. 1230-1236. (doi: 10.1093/eurheartj/ehq095)

Sofat, R. et al. (2010) Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation, 121(1), pp. 52-62. (doi: 10.1161/CIRCULATIONAHA.109.865444)

Stott, D.J. et al. (2010) Activation of Hemostasis and Decline in Cognitive Function in Older People. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(3), pp. 605-611. (doi: 10.1161/ATVBAHA.109.199448)

Thompson, A. et al. (2010) Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 375(9725), pp. 1536-1544. (doi: 10.1016/S0140-6736(10)60319-4)

2009

Di Angelantonio, E. et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA: Journal of the American Medical Association, 302(18), pp. 1993-2000. (doi: 10.1001/jama.2009.1619)

Batty, G.D., Wang, Y., Brouilette, S.W., Shiels, P.G., Packard, C.J., Moore, J., Samani, N.J. and Ford, I. (2009) Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology and Community Health, 63(10), pp. 839-841. (doi: 10.1136/jech.2009.088427)

Bell, S., Cooney, J., Packard, C.J. , Caslake, M. and Deighan, C.J. (2009) Omega-3 fatty acids improve postprandial lipaemia in patients with nephrotic range proteinuria. Atherosclerosis, 205(1), pp. 296-301. (doi: 10.1016/j.atherosclerosis.2008.12.002)

Deans, K.A. et al. (2009) Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study. British Medical Journal, 339, b4170. (doi: 10.1136/bmj.b4170)

Ford, I. et al. (2009) Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Medicine, 6(1), e1000016. (doi: 10.1371/journal.pmed.1000016)

Packard, C. (2009) Lipoprotein-associated phospholipase A(2) as a biomarker of coronary heart disease and a therapeutic target. Current Opinion in Cardiology, 24(4), pp. 358-363.

Sattar, N. et al. (2009) Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly. Diabetologia, 52(2), pp. 235-239.

2008

Caslake, M.J. et al. (2008) Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN study. American Journal of Clinical Nutrition, 88(3), pp. 618-629.

Polisecki, E. et al. (2008) Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response and cardiovascular disease incidence in PROSPER. Atherosclerosis, 200(1), pp. 109-114.

Duvillard, L., Caslake, M.J., Petit, J.M., Verges, B., Gambert, P. and Packard, C.J. (2008) Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias. Atherosclerosis, 199(1), pp. 27-33. (doi: 10.1016/j.atherosclerosis.2007.11.026)

Sattar, N. et al. (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet, 371(9628), pp. 1927-1935. (doi: 10.1016/S0140-6736(08)60602-9)

Downs, J.R. et al. (2008) Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 371(9607), pp. 117-125. (doi: 10.1016/S0140-6736(08)60104-X)

Durrington, P., Charlton-Menys, V., Packard, C., Caslake, M., Wang, J., Bhatnagar, D., Scott, J., Scott, J. and Hegele, R. (2008) Familial hypobetalipoproteinemia due to a novel early stop mutation. Journal of Clinical Lipidology, 2(5), pp. 384-390.

Poliseckia, E. et al. (2008) Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis, 200(1), pp. 95-101. (doi: 10.1016/j.atherosclerosis.2007.12.005)

Trompet, S. et al. (2008) Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study. Experimental Gerontology, 43(8), pp. 801-805. (doi: 10.1016/j.exger.2008.04.006)

Trompet, S. et al. (2008) Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain, 131(4), pp. 1069-1077. (doi: 10.1093/brain/awn023)

Velupillai, Y.N. et al. (2008) Psychological, social and biological determinants of ill health (pSoBid): study protocol of a population-based study. BMC Public Health, 8(126), (doi: 10.1186/1471-2458-8-126)

2007

Meyer, B.J., Duvillard, L., Owen, A., Packard, C.J. and Caslake, M.J. (2007) Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate. Atherosclerosis, 195(2), e28-e34. (doi: 10.1016/j.atherosclerosis.2007.01.001)

Adiels, M. et al. (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia, 50(11), pp. 2356-2365. (doi: 10.1007/s00125-007-0790-1)

Packard, C.J. et al. (2007) Association between apolipoprotein E4 and cognitive decline in elderly adults. Journal of the American Geriatrics Society, 55(11), pp. 1777-1785. (doi: 10.1111/j.1532-5415.2007.01415.x)

Gill, J.M. , Al-Mamari, A., Ferrell, W.R., Cleland, S.J., Perry, C.G., Sattar, N. , Packard, C.J. , Caslake, M.J. and Petrie, J.R. (2007) Effect of prior moderate exercise on postprandial metabolism in men with type 2 diabetes: Heterogeneity of responses. Atherosclerosis, 194(1), pp. 134-143. (doi: 10.1016/j.atherosclerosis.2006.10.007)

Geberhiwot, T., Alger, S., McKiernan, P., Packard, C. , Caslake, M., Elias, E. and Cramb, R. (2007) Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX. Journal of Inherited Metabolic Disease, 30(3), p. 406. (doi: 10.1007/s10545-007-0485-2)

Sattar, N. , McConnachie, A. , Ford, I. , Gaw, A., Cleland, S.J., Forouhi, N.G., Macfarlane, P., Shepherd, J., Cobbe, S. and Packard, C. (2007) Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study - Specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes, 56(4), pp. 984-991. (doi: 10.2337/db06-1256)

Ford, I., Murray, H., Shepherd, J., Packard, C. , Macfarlane, P. and Cobbe, S. (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine, 357(15), pp. 1477-1486. (doi: 10.1056/NEJMoa065994)

Sattar, N. et al. (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). Circulation, 115(8), pp. 981-989. (doi: 10.1161/CIRCULATIONAHA.106.643114)

Trompet, S. et al. (2007) Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events - The PROSPER study. In: Rattan, S. and Akman, S. (eds.) Biogerontology: Mechanisms and Interventions. Series: Annals of the New York Academy of Sciences (1100). Blackwell Publishing: Oxford, pp. 189-198. ISBN 978-1-57331-679-8 (doi: 10.1196/annals.1395.018)

2006

Adiels, M. et al. (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia, 49(4), pp. 755-765. (doi: 10.1007/s00125-005-0125-z)

O'Reilly, D., Upton, M.N., Caslake, M.J., Robertson, M., Norrie, J., McConnachie, A. , Watt, G.C.M. and Packard, C.J. (2006) Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation. Heart, 92(4), pp. 533-535. (doi: 10.1136/hrt.2005.063081)

Gill, J. , Al-Mamari, A., Ferrell, W., Cleland, S., Sattar, N., Packard, C. , Petrie, J. and Caslake, M. (2006) Effects of a moderate exercise session on postprandial lipoproteins, apolipoproteins and lipoprotein remnants in middle-aged men. Atherosclerosis, 185(1), pp. 87-96. (doi: 10.1016/j.atherosclerosis.2005.06.009)

Tonelli, M. et al. (2006) Letter regarding article by Tonelli et al, 'Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease' - Response. Circulation, 113(4), E59-E60.

2005

Caslake, M.J. and Packard, C.J. (2005) Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nature Clinical Practice Cardiovascular Medicine, 2(10), pp. 529-535. (doi: 10.1038/ncpcardio0321)

Packard, C.J. et al. (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 112, pp. 3058-3065. (doi: 10.1161/CIRCULATIONAHA.105.526848)

Tonelli, M. et al. (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation, 112(2), pp. 171-178. (doi: 10.1161/CIRCULATIONAHA.104.517565)

2004

Gaw, A., Packard, C.J. and Shepherd, J. (Eds.) (2004) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK. ISBN 9781841842929

Gill, J.M.R., Al-Mamari, A., Ferrell, W.R., Cleland, S.J., Packard, C.J. , Sattar, N. , Petrie, J.R. and Caslake, M.J. (2004) Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men. Journal of the American College of Cardiology, 44(12), pp. 2375-2382. (doi: 10.1016/j.jacc.2004.09.035)

Sattar, N., Scherbakova, O., Ford, I., O'Reilly, D., Stanley, A., Forrest, E., MacFarlane, P., Packard, C. , Cobbe, S. and Shepherd, J. (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes, 53(11), pp. 2855-2860. (doi: 10.2337/diabetes.53.11.2855)

Sattar, N. et al. (2004) Metabolic syndrome and diabetes mellitus - Response. Circulation, 109(3), E23-E23.

Shepherd, J. (2004) Primary prevention of coronary heart disease with statins. In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 110-122. ISBN 9781841842929

Shepherd, J. (2004) Statin therapy for the 21st century. In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 241-252. ISBN 9781841842929

Shepherd, J., Blauw, G.J., Murphy, M.G. and Gaw, A. (2004) The prospective study of pravastatin in the elderly at risk (PROSPER). In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG-CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 175-188. ISBN 9781841842929

2003

Sattar, N. et al. (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108(4), pp. 414-419. (doi: 10.1161/01.CIR.0000080897.52664.94) (PMID:12860911)

Gill, J. M.R. , Brown, J. C., Caslake, M. J., Wright, D. M., Cooney, J., Bedford, D., Hughes, D. A., Stanley, J. C. and Packard, C. J. (2003) Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. American Journal of Clinical Nutrition, 78(1), pp. 47-56. (doi: 10.1093/ajcn/78.1.47) (PMID:12816770)

2002

Ford, I. et al. (2002) A prospective study of pravastatin in the elderly at risk (PROSPER): Screening experience and baseline characteristics. Current Controlled Trials in Cardiovascular Medicine, 3, p. 8. (doi: 10.1186/1468-6708-3-8)

Freeman, D.J. , Norrie, J., Caslake, M.J., Gaw, A., Ford, I. , Lowe, G.D.O., O'Reilly, D. S. J.,, Packard, C.J. and Sattar, N. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 51(5), pp. 1596-1600. (doi: 10.2337/diabetes.51.5.1596)

Freeman, D.J. , Norrie, J., Caslake, M.J., Gaw, A., Ford, I. , Lowe, G.D.O., O'Reilly, D.S., Packard, C.J. and Sattar, N. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 51(5), pp. 1596-1600.

Sanderson, P., Gill, J.M.R. , Packard, C.J. , Sanders, T.A.B., Vessby, B. and Williams, C.M. (2002) UK Food Standards Agency cis-monounsaturated fatty acid workshop report. British Journal of Nutrition, 88(1), pp. 99-104. (doi: 10.1079/BJNBJN2002595)

Shepherd, J. et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360(9346), pp. 1623-1630. (doi: 10.1016/S0140-6736(02)11600-X)

Streja, L., Packard, C. , Shepherd, J., Cobbe, S. and Ford, I. (2002) Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology, 90(7), pp. 731-736. (doi: 10.1016/S0002-9149(02)02599-7)

2000

Packard, C.J. et al. (2000) Lipoprotein-associated phospholipse A2 as an independent predictor of coronary heart disease (WOSCOPS). New England Journal of Medicine, 343(16), pp. 1148-1155. (doi: 10.1056/NEJM200010193431603)

McColl, M.D., Sattar, N. , Ellison, J., Tait, R.C. , Walker, I.D., Packard, C.J. and Greer, I.A. (2000) Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagulation and Fibrinolysis, 11(3), pp. 225-229. (PMID:10870800)

Lowe, G., Rumley, A., Norrie, J., Ford, I. , Shepherd, J., Cobbe, S., Macfarlane, P. and Packard, C. (2000) Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study. Thrombosis and Haemostasis, 84(4), pp. 553-558.

Packard, C.J. et al. (2000) Lipoprotein-associated phospholipase A(2) as an independent predictor of coronary heart disease. New England Journal of Medicine, 343(16), pp. 1148-1155.

1998

Packard, C. , Shepherd, J., Cobbe, S., Ford, I. , Isles, C.G., McKillop, J.H., MacFarlane, P.W., Lorimer, A.R. and Norrie, J. (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation, 97(15), pp. 1440-1445.

1995

Shepherd, J., Cobbe, S.M., Ford, I. , Isles, C.G., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H. and Packard, C.J. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine, 333(20), pp. 1301-1308. (doi: 10.1056/NEJM199511163332001)

Articles

Hageman, S. H..J. et al. (2024) Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. European Journal of Preventive Cardiology, (Accepted for Publication)

Björnson, E., Adiels, M., Taskinen, M.-R., Burgess, S., Chapman, M. J., Packard, C. J. and Borén, J. (2024) Lipoprotein(a) is markedly more atherogenic than LDL an apolipoprotein B-based genetic analysis. Journal of the American College of Cardiology, 83(3), pp. 385-395. (doi: 10.1016/j.jacc.2023.10.039) (PMID:38233012)

Chapman, M. J. and Packard, C. J. (2023) Realizing the potential of PCSK9 inhibition: a novel oral macrocyclic peptide on the horizon. Journal of the American College of Cardiology, 81(16), pp. 1565-1568. (doi: 10.1016/j.jacc.2023.03.384) (PMID:37076210)

Taskinen, M.-R. et al. (2022) Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism. European Journal of Endocrinology, 187(1), pp. 75-84. (doi: 10.1530/eje-21-1187) (PMID:35521766)

Packard, C. J. (2022) Remnants, LDL, and the quantification of lipoprotein-associated risk in atherosclerotic cardiovascular disease. Current Atherosclerosis Reports, 24(3), pp. 133-142. (doi: 10.1007/s11883-022-00994-z) (PMID:35175548)

Taskinen, M.‐R. et al. (2021) Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes. Diabetes, Obesity and Metabolism, 23(5), pp. 1191-1201. (doi: 10.1111/dom.14328) (PMID:33502078)

Björnson, E. et al. (2020) Apolipoprotein B48 metabolism in chylomicrons and very low‐density lipoproteins and its role in triglyceride transport in normo‐ and hypertriglyceridemic human subjects. Journal of Internal Medicine, 288(4), pp. 422-438. (doi: 10.1111/joim.13017) (PMID:31846520)

Boren, J. et al. (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 41(24), pp. 2313-2330. (doi: 10.1093/eurheartj/ehz962) (PMID:32052833) (PMCID:PMC7308544)

Björnson, E., Packard, C. J. , Taskinen, M.‐R. and Borén, J. (2020) ‘Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate.’ – Authors’ response. Journal of Internal Medicine, 287(1), p. 118. (doi: 10.1111/joim.12997) (PMID:31631432)

Packard, C. J. (2020) Triglyceride lowering 2.0: back to the future? European Heart Journal, 41(1), pp. 95-98. (doi: 10.1093/eurheartj/ehz810) (PMID:31733059)

Taskinen, M.-R. et al. (2020) Impact of PCSK9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type 2 diabetic subjects. Journal of Clinical Lipidology, 14(1), pp. 77-87. (doi: 10.1016/j.jacl.2019.12.003) (PMID:31917184)

Packard, C. J. (2019) Strategies to alter the trajectory of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 30(6), pp. 438-445. (doi: 10.1097/MOL.0000000000000643) (PMID:31609725)

Ference, B. A. et al. (2019) Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA: Journal of the American Medical Association, 322(14), pp. 1381-1391. (doi: 10.1001/jama.2019.14120) (PMID:31475726) (PMCID:PMC6724415)

Lee, M. M.Y. , Sattar, N. , McMurray, J. J.V. and Packard, C. J. (2019) Statins in the prevention and treatment of heart failure: a review of the evidence. Current Atherosclerosis Reports, 21(10), 41. (doi: 10.1007/s11883-019-0800-z)

Taskinen, M.-R., Packard, C. J. and Borén, J. (2019) Dietary fructose and the Metabolic Syndrome. Nutrients, 11(9), e1987. (doi: 10.3390/nu11091987) (PMID:31443567)

Adiels, M. et al. (2019) Role of apolipoprotein C-III overproduction in diabetic dyslipidemia. Diabetes, Obesity and Metabolism, 21(8), pp. 1861-1870. (doi: 10.1111/dom.13744) (PMID:30972934)

Fruchart, J.-C. et al. (2019) Residual vascular risk in diabetes – will the SPPARM alpha concept hold the key? Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 13(4), pp. 2723-2725. (doi: 10.1016/j.dsx.2019.05.034) (PMID:31405699)

Fruchart, J.-C. et al. (2019) The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular Diabetology, 18(1), 71. (doi: 10.1186/s12933-019-0864-7) (PMID:31164165) (PMCID:PMC6549355)

Brazel, D. M. et al. (2019) Exome chip meta-analysis fine maps causal variants and elucidates the genetic architecture of rare coding variants in smoking and alcohol use. Biological Psychiatry, 85(11), pp. 946-955. (doi: 10.1016/j.biopsych.2018.11.024) (PMID:30679032)

Taskinen, M.-R., Packard, C. J. and Borén, J. (2019) Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Current Atherosclerosis Reports, 21(8), 27. (doi: 10.1007/s11883-019-0791-9) (PMID:31111320) (PMCID:PMC6527792)

Björnson, E. et al. (2019) Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics. Journal of Internal Medicine, 285(5), pp. 562-577. (doi: 10.1111/joim.12877) (PMID:30779243)

Armitage, J. et al. (2019) Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, 393(10170), pp. 407-415. (doi: 10.1016/S0140-6736(18)31942-1) (PMID:30712900) (PMCID:PMC6429627)

Ference, B. A. et al. (2019) Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA: Journal of the American Medical Association, 321(4), pp. 364-373. (doi: 10.1001/jama.2018.20045) (PMID:30694319) (PMCID:PMC6439767)

Robinson, J. G. et al. (2018) Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life. Journal of the American Heart Association, 7(20), e009778. (doi: 10.1161/JAHA.118.009778) (PMID:30371276) (PMCID:PMC6474943)

Packard, C. J. (2018) Determinants of achieved LDL cholesterol and "Non-HDL" cholesterol in the management of dyslipidemias. Current Cardiology Reports, 20(8), 60. (doi: 10.1007/s11886-018-1003-x) (PMID:29904807)

Annemans, L., Packard, C. J. , Briggs, A. and Ray, K. K. (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 39(27), pp. 2546-2550. (doi: 10.1093/eurheartj/ehx710) (PMID:29236976) (PMCID:PMC6047410)

Fisk, H. L. et al. (2018) Association of oily fish intake, sex, age, BMI and APOE genotype with plasma long-chain n-3 fatty acid composition. British Journal of Nutrition, 120(1), pp. 23-32. (doi: 10.1017/S000711451800106X) (PMID:29729672)

Burgess, S. et al. (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies. JAMA Cardiology, 3(7), pp. 619-627. (doi: 10.1001/jamacardio.2018.1470) (PMID:29926099)

Packard, C. J. (2018) LDL cholesterol: how low to go? Trends in Cardiovascular Medicine, 28(5), pp. 348-354. (doi: 10.1016/j.tcm.2017.12.011) (PMID:29336946)

Vallejo-Vaz, A. J., Packard, C. J. and Ray, K. K. (2018) Response by Vallejo-Vaz et al to letters regarding article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up". Circulation, 137(22), pp. 2419-2420. (doi: 10.1161/CIRCULATIONAHA.118.033781) (PMID:29844078)

Turcot, V. et al. (2018) Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 50(1), pp. 26-41. (doi: 10.1038/s41588-017-0011-x) (PMID:29273807) (PMCID:PMC5945951)

Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J. , Ford, I. and Ray, K. K. (2017) Low-density lipoprotein-cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein-cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation, 136(20), pp. 1878-1891. (doi: 10.1161/CIRCULATIONAHA.117.027966) (PMID:28877913)

Packard, C. J. , Young, R. , Ross, K., Ford, I. , Ambegaonkar, B. M., Brudi, P. and McCowan, C. (2017) Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. European Heart Journal: Quality of Care and Clinical Outcomes, 3(4), pp. 281-288. (doi: 10.1093/ehjqcco/qcx012) (PMID:29044395)

Robertson, J., Porter, D., Sattar, N. , Packard, C. J. , Caslake, M., McInnes, I. and McCarey, D. (2017) Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(11), pp. 1949-1952. (doi: 10.1136/annrheumdis-2017-211708) (PMID:28916714)

Ference, B. A. et al. (2017) Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA: Journal of the American Medical Association, 318(10), pp. 947-956. (doi: 10.1001/jama.2017.11467) (PMID:28846118) (PMCID:PMC5710502)

Ference, B. A. et al. (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), pp. 2459-2472. (doi: 10.1093/eurheartj/ehx144) (PMID:28444290)

Gregson, J. M. et al. (2017) Genetic invalidation of Lp-PLA2 as a therapeutic target: large-scale study of five functional Lp-PLA2-lowering alleles. European Journal of Preventive Cardiology, 24(5), pp. 492-504. (doi: 10.1177/2047487316682186) (PMID:27940953)

Sodi, R., Eastwood, J., Caslake, M., Packard, C. J. and Denby, L. (2017) Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. Clinica Chimica Acta, 466, pp. 13-19. (doi: 10.1016/j.cca.2016.12.031) (PMID:28062296)

Marouli, E. et al. (2017) Rare and low-frequency coding variants alter human adult height. Nature, 542(7640), pp. 186-190. (doi: 10.1038/nature21039) (PMID:28146470) (PMCID:PMC5302847)

Bassendine, M.F., Nielsen, S.U., Bridge, S.H., Felmlee, D.J., Sheridan, D.A., Packard, C.J. and Neely, R.D. (2017) Hepatitis C virus and atherosclerosis: a legacy after virologic cure? Clinics and Research in Hepatology and Gastroenterology, 41(1), pp. 25-30. (doi: 10.1016/j.clinre.2016.09.008) (PMID:27840032)

Packard, C. J. (2017) Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism. Circulation, 135(4), pp. 363-365. (doi: 10.1161/CIRCULATIONAHA.116.025897) (PMID:28115413)

Ford, I. , Shah, A. S.V., Zhang, R., McAllister, D. A. , Strachan, F. E., Caslake, M., Newby, D. E., Packard, C. J. and Mills, N. L. (2016) High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. Journal of the American College of Cardiology, 68(25), pp. 2719-2728. (doi: 10.1016/j.jacc.2016.10.020) (PMID:28007133) (PMCID:PMC5176330)

Surendran, P. et al. (2016) Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 48(10), pp. 1151-1161. (doi: 10.1038/ng.3654) (PMID:27618447) (PMCID:PMC5056636)

Scott, R. A. et al. (2016) A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 8(341), 341ra76. (doi: 10.1126/scitranslmed.aad3744) (PMID:27252175)

Ford, I. , Murray, H., Mccowan, C. and Packard, C. J. (2016) Long term safety and efficacy of lowering LDL cholesterol with statin therapy: 20-year follow-up of West of Scotland coronary prevention study. Circulation, 133(11), pp. 1073-1080. (doi: 10.1161/CIRCULATIONAHA.115.019014) (PMID:26864092) (PMCID:PMC4894764)

Zanoni, P. et al. (2016) Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 351(6278), pp. 1166-1171. (doi: 10.1126/science.aad3517) (PMID:26965621) (PMCID:PMC4889017)

Minihane, A. M. et al. (2016) Consumption of fish oil providing amounts of eicosapentaenoic acid and docosahexaenoic acid that can be obtained from the diet reduces blood pressure in adults with systolic hypertension: a retrospective analysis. Journal of Nutrition, 146(3), pp. 516-523. (doi: 10.3945/jn.115.220475) (PMID:26817716)

Packard, C. and Ford, I. (2015) Long-term follow-up of lipid-lowering trials. Current Opinion in Lipidology, 26(6), pp. 572-579. (doi: 10.1097/mol.0000000000000230) (PMID:26780010)

Packard, C. J. , Weintraub, W. S. and Laufs, U. (2015) New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. Vascular Pharmacology, 71, pp. 37-39. (doi: 10.1016/j.vph.2015.03.008) (PMID:25889746)

Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi: 10.1093/eurheartj/ehv072) (PMID:25802390) (PMCID:PMC4769322)

Cholesterol Treatment Trialists’ (CTT) Collaboration, and , (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet, 385(9976), pp. 1397-1405. (doi: 10.1016/S0140-6736(14)61368-4)

van Leeuwen, E. M. et al. (2015) Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels. Nature Communications, 6, 6065. (doi: 10.1038/ncomms7065) (PMID:25751400) (PMCID:PMC4366498)

Akao, H. et al. (2014) ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. Atherosclerosis, 235(1), pp. 176-181. (doi: 10.1016/j.atherosclerosis.2014.04.030) (PMID:24854628)

Preiss, D. and Packard, C. J. (2014) Emerging therapeutic approaches to treat dyslipidemia. Current Cardiology Reports, 16(7), (doi: 10.1007/s11886-014-0506-3) (PMID:24890766)

Preiss, D. , Lloyd, S. M. , Ford, I. , McMurray, J. J.V. , Holman, R. R., Welsh, P. , Fisher, M., Packard, C. J. and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi: 10.1016/S2213-8587(13)70152-9) (PMID:24622715)

Laufs, U., Descamps, O. S., Catapano, A. L. and Packard, C. J. (2014) Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. European Heart Journal, 35(30), pp. 1996-2000. (doi: 10.1093/eurheartj/ehu228)

McConnachie, A. , Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C.J. , Cobbe, S.M. and Ford, I. (2014) Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal, 35(5), pp. 290-298. (doi: 10.1093/eurheartj/eht232)

Cavanagh, J. et al. (2013) Socioeconomic status and the cerebellar grey matter volume. Data from a well-characterised population sample. Cerebellum, 12(6), pp. 882-891. (doi: 10.1007/s12311-013-0497-4)

Krishnadas, R. , Kim, J., Mclean, J., Batty, D., Mclean, J., Millar, K., Packard, C. and Cavanagh, J. (2013) The envirome and the connectome: exploring the structural noise in the human brain associated with socioeconomic deprivation. Frontiers in Human Neuroscience, 7(722), (doi: 10.3389/fnhum.2013.00722)

Krishnadas, R. et al. (2013) Socioeconomic deprivation and cortical morphology: psychological, social, and biological determinants of ill health study. Psychosomatic Medicine, 75(7), pp. 616-623. (doi: 10.1097/PSY.0b013e3182a151a7)

Krishnadas, R. et al. (2013) Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: results from the psychological, social and biological determinants of ill health (pSoBid) study. NeuroImage: Clinical, 2(2013), pp. 646-657. (doi: 10.1016/j.nicl.2013.04.012)

Laufs, U., Weintraub, W.S. and Packard, C.J. (2013) Beyond statins: what to expect from add-on lipid regulating therapy? European Heart Journal, 34(34), pp. 2660-2665. (doi: 10.1093/eurheartj/eht213)

Lloyd, S.M. et al. (2013) Long-term effects of statin treatment in elderly people: Extended follow-up of the PROspective study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE, 8(9), e72642. (doi: 10.1371/journal.pone.0072642) (PMID:24023757) (PMCID:PMC3759378)

Millar, K. et al. (2013) Personality, socio-economic status and inflammation: cross-sectional, population-based study. PLoS ONE, 8(3), e58256. (doi: 10.1371/journal.pone.0058256) (PMID:23516457) (PMCID:PMC3596406)

Welsh, P. , Doolin, O., Willeit, P., Packard, C. , Macfarlane, P., Cobbe, S., Gudnason, V., Di Angelantonio, E., Ford, I. and Sattar, N. (2013) N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. European Heart Journal, 34(6), pp. 443-450. (doi: 10.1093/eurheartj/ehs239)

McLean, J. et al. (2012) Early life socioeconomic status, chronic physiological stress and hippocampal N-acetyl aspartate concentrations. Behavioural Brain Research, 235(2), pp. 225-230. (doi: 10.1016/j.bbr.2012.08.013)

Packard, C. et al. (2012) Interaction of personality traits with social deprivation in determining mental wellbeing and health behaviours. Journal of Public Health, 34(4), pp. 615-624. (doi: 10.1093/pubmed/fds030)

Miller, A. M. et al. (2012) Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS ONE, 7(10), e47830. (doi: 10.1371/journal.pone.0047830) (PMID:23112853) (PMCID:PMC3480428)

Kaptoge, S. et al. (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. New England Journal of Medicine, 367(14), pp. 1310-1320. (doi: 10.1056/NEJMoa1107477)

Mihaylova, B. et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 380(9841), pp. 581-590. (doi: 10.1016/S0140-6736(12)60367-5)

Knox, S. et al. (2012) 25-hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis, 223(2), pp. 437-441. (doi: 10.1016/j.atherosclerosis.2012.05.001) (PMID:22632919)

Di Angelantonio, E. et al. (2012) Lipid-related markers and cardiovascular disease prediction. JAMA: Journal of the American Medical Association, 307(23), pp. 2499-2506. (doi: 10.1001/jama.2012.6571)

Martin, N.G., Li, K.W., Murray, H., Putt, W., Packard, C.J. and Humphries, S.E. (2012) The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. British Journal of Clinical Pharmacology, 73(2), pp. 303-306. (doi: 10.1111/j.1365-2125.2011.04090.x)

McGuinness, D. et al. (2012) Socio-economic status is associated with epigenetic differences in the pSoBid cohort. International Journal of Epidemiology, 41(1), pp. 151-160. (doi: 10.1093/ije/dyr215)

Akao, H. et al. (2012) Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis, 220(2), pp. 413-417. (doi: 10.1016/j.atherosclerosis.2011.09.028)

Akao, H. et al. (2012) KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis, 220(2), pp. 456-462. (doi: 10.1016/j.atherosclerosis.2011.11.037)

Charchar, F.J. et al. (2012) Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet, 379(9819), pp. 915-922. (doi: 10.1016/S0140-6736(11)61453-0)

Emberson, J.R. et al. (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE, 7(1), e29849. (doi: 10.1371/journal.pone.0029849) (PMID:22276132) (PMCID:PMC3261846)

Kofler, B.M. et al. (2012) Apolipoprotein E genotype and the cardiovascular disease risk phenotype: Impact of sex and adiposity (the FINGEN study). Atherosclerosis, 221(2), pp. 467-470. (doi: 10.1016/j.atherosclerosis.2012.01.042)

Poortvliet, R.K.E. et al. (2012) Blood pressure variability and cardiovascular risk in the PROspective study of pravastatin in the elderly at risk (PROSPER). PLoS ONE, 7(12), e52438. (doi: 10.1371/journal.pone.0052438) (PMID:23285043) (PMCID:PMC3527505)

Shiffman, D. et al. (2012) Genome-wide study of gene variants associated with differential cardiovascular event reduction by Pravastatin therapy. PLoS ONE, 7(5), e38240. (doi: 10.1371/journal.pone.0038240) (PMID:22666496) (PMCID:PMC3364212)

Ford, I. et al. (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology, 40(6), pp. 1530-1538. (doi: 10.1093/ije/dyr172)

van Es, A.C.G.M. et al. (2011) Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology, 77(15), pp. 1446-1452. (doi: 10.1212/WNL.0b013e318232ab1d)

Welsh, P. et al. (2011) Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(10), pp. 2338-2344. (doi: 10.1161/ATVBAHA.111.231795) (PMID:21757655)

Widya, R. L. et al. (2011) Increased amygdalar and hippocampal volumes in elderly obese individuals with or at risk of cardiovascular disease. American Journal of Clinical Nutrition, 93(6), pp. 1190-1195. (doi: 10.3945/ajcn.110.006304)

Logue, J. , Murray, H.M., Welsh, P. , Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2011) Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart, 97(7), pp. 564-568. (doi: 10.1136/hrt.2010.211201)

Rahimi, K. et al. (2011) Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. British Medical Journal, 342, d1250. (doi: 10.1136/bmj.d1250)

Wensley, F. et al. (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. British Medical Journal, 342, d548-d548. (doi: 10.1136/bmj.d548)

Moran, C.N., Barwell, N.D., Malkova, D. , Cleland, S., McPhee, I., Packard, C.J. , Zammit, V.A. and Gill, J.M.R. (2011) Effects of diabetes family history and exercise training on the expression of adiponectin and leptin and their receptors. Metabolism, 60(2), pp. 206-214. (doi: 10.1016/j.metabol.2009.12.026)

Li, Y. et al. (2011) Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics, 129(1), pp. 17-23. (doi: 10.1007/s00439-010-0892-6)

Mutsaerts, H.J.M.M. et al. (2011) Diastolic carotid artery wall shear stress is associated with cerebral infarcts and periventricular white matter lesions. Stroke, 42(12), pp. 3497-3501. (doi: 10.1161/STROKEAHA.111.614453)

Packard, C.J. et al. (2011) Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study. BMC Public Health, 11, p. 42. (doi: 10.1186/1471-2458-11-42)

Pons, D. et al. (2011) Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. Heart, 97(2), pp. 143-150. (doi: 10.1136/hrt.2010.199927)

Shiels, P.G. et al. (2011) Accelerated telomere attrition is associated with relative household income, diet and inflammation in the pSoBid cohort. PLoS ONE, 6(7), e22521. (doi: 10.1371/journal.pone.0022521)

Felmlee, D. J. et al. (2010) Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology, 139(5), pp. 1774-1783. (doi: 10.1053/j.gastro.2010.07.047) (PMID:20682323)

Caslake, M.J. et al. (2010) Lipoprotein-associated phospholipase A₂ inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis, 210(1), pp. 28-34. (doi: 10.1016/j.atherosclerosis.2009.10.041)

Polisecki, E. et al. (2010) Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 51(5), pp. 1201-1207. (doi: 10.1194/jlr.P001172)

Olano-Martin, E., Anil, E., Caslake, M.J., Packard, C.J. , Bedford, D., Stewart, G., Peiris, D., Williams, C.M. and Minihane, A.M. (2010) Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis, 209(1), pp. 104-110. (doi: 10.1016/j.atherosclerosis.2009.08.024)

Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi: 10.1016/S0140-6736(09)61965-6)

Matthan, N.R., Resteghini, N., Robertson, M., Ford, I. , Shepherd, J., Packard, C. , Buckley, B.M., Jukema, J.W., Lichenstein, A.H. and Schaefer, E.J. (2010) Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. Journal of Lipid Research, 51, pp. 202-209. (doi: 10.1194/jlr.M900032-JLR200)

Trompet, S. et al. (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology, 257(1), pp. 85-90. (doi: 10.1007/s00415-009-5271-7)

Welsh, P. et al. (2010) Unraveling the directional link between adiposity and inflammation: a bidirectional mendelian randomization approach. Journal of Clinical Endocrinology and Metabolism, 95(1), pp. 93-99. (doi: 10.1210/jc.2009-1064)

Dow, D.J., McMahon, A.D. , Gray, I.C., Packard, C.J. and Groot, P.H.E. (2010) CCR2 and coronary artery disease: a woscops substudy. BMC Research Notes, 3(1), p. 31. (doi: 10.1186/1756-0500-3-31)

Preiss, D. , Welsh, P. , Murray, H., Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up(dagger). European Heart Journal, 31(10), pp. 1230-1236. (doi: 10.1093/eurheartj/ehq095)

Sofat, R. et al. (2010) Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation, 121(1), pp. 52-62. (doi: 10.1161/CIRCULATIONAHA.109.865444)

Stott, D.J. et al. (2010) Activation of Hemostasis and Decline in Cognitive Function in Older People. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(3), pp. 605-611. (doi: 10.1161/ATVBAHA.109.199448)

Thompson, A. et al. (2010) Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 375(9725), pp. 1536-1544. (doi: 10.1016/S0140-6736(10)60319-4)

Di Angelantonio, E. et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA: Journal of the American Medical Association, 302(18), pp. 1993-2000. (doi: 10.1001/jama.2009.1619)

Batty, G.D., Wang, Y., Brouilette, S.W., Shiels, P.G., Packard, C.J., Moore, J., Samani, N.J. and Ford, I. (2009) Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology and Community Health, 63(10), pp. 839-841. (doi: 10.1136/jech.2009.088427)

Bell, S., Cooney, J., Packard, C.J. , Caslake, M. and Deighan, C.J. (2009) Omega-3 fatty acids improve postprandial lipaemia in patients with nephrotic range proteinuria. Atherosclerosis, 205(1), pp. 296-301. (doi: 10.1016/j.atherosclerosis.2008.12.002)

Deans, K.A. et al. (2009) Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study. British Medical Journal, 339, b4170. (doi: 10.1136/bmj.b4170)

Ford, I. et al. (2009) Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Medicine, 6(1), e1000016. (doi: 10.1371/journal.pmed.1000016)

Packard, C. (2009) Lipoprotein-associated phospholipase A(2) as a biomarker of coronary heart disease and a therapeutic target. Current Opinion in Cardiology, 24(4), pp. 358-363.

Sattar, N. et al. (2009) Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly. Diabetologia, 52(2), pp. 235-239.

Caslake, M.J. et al. (2008) Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN study. American Journal of Clinical Nutrition, 88(3), pp. 618-629.

Polisecki, E. et al. (2008) Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response and cardiovascular disease incidence in PROSPER. Atherosclerosis, 200(1), pp. 109-114.

Duvillard, L., Caslake, M.J., Petit, J.M., Verges, B., Gambert, P. and Packard, C.J. (2008) Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias. Atherosclerosis, 199(1), pp. 27-33. (doi: 10.1016/j.atherosclerosis.2007.11.026)

Sattar, N. et al. (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet, 371(9628), pp. 1927-1935. (doi: 10.1016/S0140-6736(08)60602-9)

Downs, J.R. et al. (2008) Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 371(9607), pp. 117-125. (doi: 10.1016/S0140-6736(08)60104-X)

Durrington, P., Charlton-Menys, V., Packard, C., Caslake, M., Wang, J., Bhatnagar, D., Scott, J., Scott, J. and Hegele, R. (2008) Familial hypobetalipoproteinemia due to a novel early stop mutation. Journal of Clinical Lipidology, 2(5), pp. 384-390.

Poliseckia, E. et al. (2008) Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis, 200(1), pp. 95-101. (doi: 10.1016/j.atherosclerosis.2007.12.005)

Trompet, S. et al. (2008) Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study. Experimental Gerontology, 43(8), pp. 801-805. (doi: 10.1016/j.exger.2008.04.006)

Trompet, S. et al. (2008) Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain, 131(4), pp. 1069-1077. (doi: 10.1093/brain/awn023)

Velupillai, Y.N. et al. (2008) Psychological, social and biological determinants of ill health (pSoBid): study protocol of a population-based study. BMC Public Health, 8(126), (doi: 10.1186/1471-2458-8-126)

Meyer, B.J., Duvillard, L., Owen, A., Packard, C.J. and Caslake, M.J. (2007) Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate. Atherosclerosis, 195(2), e28-e34. (doi: 10.1016/j.atherosclerosis.2007.01.001)

Adiels, M. et al. (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia, 50(11), pp. 2356-2365. (doi: 10.1007/s00125-007-0790-1)

Packard, C.J. et al. (2007) Association between apolipoprotein E4 and cognitive decline in elderly adults. Journal of the American Geriatrics Society, 55(11), pp. 1777-1785. (doi: 10.1111/j.1532-5415.2007.01415.x)

Gill, J.M. , Al-Mamari, A., Ferrell, W.R., Cleland, S.J., Perry, C.G., Sattar, N. , Packard, C.J. , Caslake, M.J. and Petrie, J.R. (2007) Effect of prior moderate exercise on postprandial metabolism in men with type 2 diabetes: Heterogeneity of responses. Atherosclerosis, 194(1), pp. 134-143. (doi: 10.1016/j.atherosclerosis.2006.10.007)

Geberhiwot, T., Alger, S., McKiernan, P., Packard, C. , Caslake, M., Elias, E. and Cramb, R. (2007) Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX. Journal of Inherited Metabolic Disease, 30(3), p. 406. (doi: 10.1007/s10545-007-0485-2)

Sattar, N. , McConnachie, A. , Ford, I. , Gaw, A., Cleland, S.J., Forouhi, N.G., Macfarlane, P., Shepherd, J., Cobbe, S. and Packard, C. (2007) Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study - Specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes, 56(4), pp. 984-991. (doi: 10.2337/db06-1256)

Ford, I., Murray, H., Shepherd, J., Packard, C. , Macfarlane, P. and Cobbe, S. (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine, 357(15), pp. 1477-1486. (doi: 10.1056/NEJMoa065994)

Sattar, N. et al. (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). Circulation, 115(8), pp. 981-989. (doi: 10.1161/CIRCULATIONAHA.106.643114)

Adiels, M. et al. (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia, 49(4), pp. 755-765. (doi: 10.1007/s00125-005-0125-z)

O'Reilly, D., Upton, M.N., Caslake, M.J., Robertson, M., Norrie, J., McConnachie, A. , Watt, G.C.M. and Packard, C.J. (2006) Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation. Heart, 92(4), pp. 533-535. (doi: 10.1136/hrt.2005.063081)

Gill, J. , Al-Mamari, A., Ferrell, W., Cleland, S., Sattar, N., Packard, C. , Petrie, J. and Caslake, M. (2006) Effects of a moderate exercise session on postprandial lipoproteins, apolipoproteins and lipoprotein remnants in middle-aged men. Atherosclerosis, 185(1), pp. 87-96. (doi: 10.1016/j.atherosclerosis.2005.06.009)

Tonelli, M. et al. (2006) Letter regarding article by Tonelli et al, 'Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease' - Response. Circulation, 113(4), E59-E60.

Caslake, M.J. and Packard, C.J. (2005) Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nature Clinical Practice Cardiovascular Medicine, 2(10), pp. 529-535. (doi: 10.1038/ncpcardio0321)

Packard, C.J. et al. (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 112, pp. 3058-3065. (doi: 10.1161/CIRCULATIONAHA.105.526848)

Tonelli, M. et al. (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation, 112(2), pp. 171-178. (doi: 10.1161/CIRCULATIONAHA.104.517565)

Gill, J.M.R., Al-Mamari, A., Ferrell, W.R., Cleland, S.J., Packard, C.J. , Sattar, N. , Petrie, J.R. and Caslake, M.J. (2004) Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men. Journal of the American College of Cardiology, 44(12), pp. 2375-2382. (doi: 10.1016/j.jacc.2004.09.035)

Sattar, N., Scherbakova, O., Ford, I., O'Reilly, D., Stanley, A., Forrest, E., MacFarlane, P., Packard, C. , Cobbe, S. and Shepherd, J. (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes, 53(11), pp. 2855-2860. (doi: 10.2337/diabetes.53.11.2855)

Sattar, N. et al. (2004) Metabolic syndrome and diabetes mellitus - Response. Circulation, 109(3), E23-E23.

Sattar, N. et al. (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108(4), pp. 414-419. (doi: 10.1161/01.CIR.0000080897.52664.94) (PMID:12860911)

Gill, J. M.R. , Brown, J. C., Caslake, M. J., Wright, D. M., Cooney, J., Bedford, D., Hughes, D. A., Stanley, J. C. and Packard, C. J. (2003) Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. American Journal of Clinical Nutrition, 78(1), pp. 47-56. (doi: 10.1093/ajcn/78.1.47) (PMID:12816770)

Ford, I. et al. (2002) A prospective study of pravastatin in the elderly at risk (PROSPER): Screening experience and baseline characteristics. Current Controlled Trials in Cardiovascular Medicine, 3, p. 8. (doi: 10.1186/1468-6708-3-8)

Freeman, D.J. , Norrie, J., Caslake, M.J., Gaw, A., Ford, I. , Lowe, G.D.O., O'Reilly, D. S. J.,, Packard, C.J. and Sattar, N. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 51(5), pp. 1596-1600. (doi: 10.2337/diabetes.51.5.1596)

Freeman, D.J. , Norrie, J., Caslake, M.J., Gaw, A., Ford, I. , Lowe, G.D.O., O'Reilly, D.S., Packard, C.J. and Sattar, N. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 51(5), pp. 1596-1600.

Sanderson, P., Gill, J.M.R. , Packard, C.J. , Sanders, T.A.B., Vessby, B. and Williams, C.M. (2002) UK Food Standards Agency cis-monounsaturated fatty acid workshop report. British Journal of Nutrition, 88(1), pp. 99-104. (doi: 10.1079/BJNBJN2002595)

Shepherd, J. et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360(9346), pp. 1623-1630. (doi: 10.1016/S0140-6736(02)11600-X)

Streja, L., Packard, C. , Shepherd, J., Cobbe, S. and Ford, I. (2002) Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology, 90(7), pp. 731-736. (doi: 10.1016/S0002-9149(02)02599-7)

Packard, C.J. et al. (2000) Lipoprotein-associated phospholipse A2 as an independent predictor of coronary heart disease (WOSCOPS). New England Journal of Medicine, 343(16), pp. 1148-1155. (doi: 10.1056/NEJM200010193431603)

McColl, M.D., Sattar, N. , Ellison, J., Tait, R.C. , Walker, I.D., Packard, C.J. and Greer, I.A. (2000) Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagulation and Fibrinolysis, 11(3), pp. 225-229. (PMID:10870800)

Lowe, G., Rumley, A., Norrie, J., Ford, I. , Shepherd, J., Cobbe, S., Macfarlane, P. and Packard, C. (2000) Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study. Thrombosis and Haemostasis, 84(4), pp. 553-558.

Packard, C.J. et al. (2000) Lipoprotein-associated phospholipase A(2) as an independent predictor of coronary heart disease. New England Journal of Medicine, 343(16), pp. 1148-1155.

Packard, C. , Shepherd, J., Cobbe, S., Ford, I. , Isles, C.G., McKillop, J.H., MacFarlane, P.W., Lorimer, A.R. and Norrie, J. (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation, 97(15), pp. 1440-1445.

Shepherd, J., Cobbe, S.M., Ford, I. , Isles, C.G., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H. and Packard, C.J. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine, 333(20), pp. 1301-1308. (doi: 10.1056/NEJM199511163332001)

Book Sections

Trompet, S. et al. (2007) Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events - The PROSPER study. In: Rattan, S. and Akman, S. (eds.) Biogerontology: Mechanisms and Interventions. Series: Annals of the New York Academy of Sciences (1100). Blackwell Publishing: Oxford, pp. 189-198. ISBN 978-1-57331-679-8 (doi: 10.1196/annals.1395.018)

Shepherd, J. (2004) Primary prevention of coronary heart disease with statins. In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 110-122. ISBN 9781841842929

Shepherd, J. (2004) Statin therapy for the 21st century. In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 241-252. ISBN 9781841842929

Shepherd, J., Blauw, G.J., Murphy, M.G. and Gaw, A. (2004) The prospective study of pravastatin in the elderly at risk (PROSPER). In: Gaw, A., Packard, C.J. and Shepherd, J. (eds.) Statins: The HMG-CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK, pp. 175-188. ISBN 9781841842929

Edited Books

Gaw, A., Packard, C.J. and Shepherd, J. (Eds.) (2004) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz: London, UK. ISBN 9781841842929